11 assets in Ovarian Mucinous Adenocarcinoma

Therapeutic assets addressing Ovarian Mucinous Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Ovarian Mucinous Adenocarcinoma	Ohio State University Comprehensive Cancer Center	P3	BBB (74)
Cis-Diamminedichloroplatinum Ii Ovarian Mucinous Adenocarcinoma	Ohio State University Comprehensive Cancer Center	P3	BB (70)
Adriamycin Ovarian Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	B (60)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Ovarian Mucinous Adenocarcinoma	Mayo Clinic	P2	B (59)
Cediranib Ovarian Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Durvalumab Ovarian Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Ovarian Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Ovarian Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nogitecan Ovarian Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Ovarian Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Amt-151 Ovarian Mucinous Adenocarcinoma	Multitude Therapeutics Inc.	P1	CC (43)